Dataset from Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge

The study is designed to establish infectivity of Plasmodium falciparum sporozoites (PfSPZ)
via intravenous (IV) administration in three groups with different malaria immunity-status:

1. Adults with a history of lifelong malaria exposure without sickle cell trait (HbAA)

2. Adults with a history of lifelong malaria exposure with sickle cell trait (HbAS)

3. Adults without previous malaria episodes without sickle cell trait (HbAA)

Initially a dose of 3,200 PfSPZ will be given and the time until thick blood smear positivity
after challenge will be assessed. If in any of the groups with a history of lifelong malaria
exposure, 50% or less of individuals become thick blood smear positive during the 28 days
post injection of PfSPZ Challenge, the dose will be increased 4-fold to 12,800 PfSPZ in this
group.